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Interplacental uterine expression of genes involved
in prostaglandin synthesis during canine pregnancy
and at induced prepartum luteolysis/abortion
Mariusz P Kowalewski1*, Ewa Kautz1, Elisabeth Högger1, Bernd Hoffmann2 and Alois Boos1
Abstract
Background: In the non-pregnant dog, ovarian cyclicity is independent of a uterine luteolysin. This is in contrast to
pregnant animals where a prepartum increase of luteolytic PGF2α occurs, apparently originating in the pregnant
uterus. Recently, the placenta as a source of prepartum prostaglandins (PGs) was investigated, indicating fetal
trophoblast cells as the likely main source. However, the possible contribution of uterine interplacental tissues to
the production of these hormones has not yet been thoroughly examined in the dog.
Methods: Several key factors involved in the production and/or actions of PGs were studied: cyclooxygenase 2
(COX2, PTGS2), PGF2α-synthase (PGFS/AKR1C3), PGE2-synthase (PGES), and the respective receptors FP (PTGFR), EP2
(PTGER2) and EP4 (PGTER4), 15-hydroxyprostaglandin dehydrogenase (HPGD), PG-transporter (PGT, SLCO2A1) and
progesterone receptor. Their expression and localization patterns were assessed by Real Time PCR and immunohistology
in the interplacental uterine sites from pregnant dogs during the pre-implantation period (days 8–12), post-implantation
(days 18–25), mid-gestation (days 35–40) and during antigestagen-induced luteolysis/abortion.
Results: Whereas only low COX2 expression was observed in uterine samples at all the selected time points, expression
of PGFS/AKR1C3 strongly increased post-implantation. A gradual increase in PGES-mRNA expression was noted towards
mid-gestation. FP-mRNA expression decreased significantly with the progression of pregnancy until mid-gestation. This
was associated with clearly detectable expression of HPGD, which did not change significantly over time. The expression
of FP and EP2-mRNA decreased significantly over time while EP4-mRNA expression remained unaffected. The
antigestagen-treatment led to a significant increase in expression of COX2, PGES, EP2 and PGT (SLCO2A1) mRNA. COX2
was localized predominantly in the myometrium. The expression of PGFS/AKR1C3, which was unchanged, was localized
mostly to the surface luminal epithelium. The expression of EP4, PGT and HPGH did not change during treatment, they
were co-localized with PGES and EP2 in all uterine compartments.
Conclusions: The data clearly demonstrate the basic capability of the canine pregnant uterus to produce and respond
to PGs and suggests their functions both as local regulatory factors involved in the establishment and maintenance of
pregnancy, as well as potential contributors to the process of parturition, supporting the myometrial contractility
associated with fetal expulsion.
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Background
In the domestic dog (Canis familiaris), the establishment
and maintenance of pregnancy depend on the luteal
provision of progesterone (P4) as the only source of this
hormone both during gestation and in the non-pregnant
cycle [1,2]. Luteal function is similar in both pregnant
and non-pregnant bitches (see reviews in [3-5]). The
circulating P4 levels start to deviate strongly only shortly
prior to term on days 62/63, when a steep decline marks
onset of prepartum luteolysis 12-24 h before the first
clinical signs of labour become visible [6,7]. In non-
pregnant animals, in contrast, luteal regression continues
beyond this point of time and circulating P4 concentrations
decrease slowly until levels below 1 ng/ml are reached
about 10 to 20 days later and the cycle enters the phase of
obligatory sexual quiescence, i.e., anoestrus [6]. Conse-
quently, in contrast to what is observed in non-pregnant
dogs, prepartum luteolysis appears to be a process gov-
erned by active regulatory mechanisms. In respect to
luteolytic factors, normal cyclic ovarian steroidogenic
function has been observed in hysterectomized bitches,
as in cats and primates, rendering luteal function as in-
dependent of a uterine luteolysin (prostaglandin (PG)
F2α; PGF2α) in these species [8,9]. This is in contrast
to livestock, where ovarian cyclicity is maintained due
to periodic production and secretion of uterine PGF2α.
In dogs, prostaglandins synthesized locally within the
corpus luteum appear to be involved in luteal mainten-
ance rather than in luteolysis/regression, as indicated by
increased expression of cyclooxygenase 2 (COX2, PTGS2)
and PGE2-synthase (PGES) at the beginning of the canine
luteal phase [10-12]. This hypothesis has been substanti-
ated recently by showing a luteotrophic role of PGE2 in
canine lutein cells in vitro. Acting mostly at the level of
substrate provision facilitated by steroidogenic acute
regulatory (STAR) protein expression and function, and
not at the level of activity of the two major steroidogenic
enzymes, 3βHSD and P450scc enzyme, PGE2 significantly
increased progesterone output in lutein cells [13].
In pregnant animals the prepartum luteolysis is con-
comitant with a rapid increase of PGF2α in maternal
peripheral blood, implying its involvement during pre-
partum luteolysis and/or fetal expulsion [14-16]. With re-
gard to the endocrine mechanisms regulating the process
of parturition in the dog, most of the currently available
knowledge relates to the endocrine capabilities of the
utero-placental compartments, comprising the placenta
with its adjacent uterine tissues [15,17-20]. Recent investi-
gations into the expression of factors involved in prosta-
glandin synthesis and function, the so-called PG-system,
have indicated an upregulated expression of COX2 in fetal
trophoblast cells as the possible origin of prepartum
PGF2α release within the utero-placental compartment
[15]. This finding corroborates the observation from the
same study that interfering with P4 receptor (PGR) func-
tion by application of an antigestagen in mid-pregnant
dogs leads to upregulation of utero-placental COX2
expression, mostly in the fetal trophoblast, and results
in significantly elevated peripheral PGF2α concentrations.
The only known canine-specific PGF2α-synthase (PGFS),
classified as aldo-keto reductase family 1, member C3
(AKR1C3) which is responsible for the direct conversion
of PGH2 to PGF2α, was localized in epithelial cells of
the superficial uterine glands, the so-called glandular
chambers, and in fetal trophoblasts [17]. Interestingly,
however, expression of this enzyme was decreased during
prepartum luteolysis. This was paralleled by the reduced
expression of 15-hydroxyprostaglandin dehydrogenase
(HPGD), an enzyme catabolising PGF2α and PGE2 to
their inactive metabolites [17]. Together with the con-
comitantly increased expression of PGE2-synthase (PGES)
[15], a possible functional interrelationship between these
entities has been suggested. The potential involvement of
alternative pathways for PGF2α synthesis has not, however,
yet been investigated. It is noteworthy that the results to
date clearly show that there is no parturition-related
increase in estrogens mediating the prepartum PGF2α
release, and the sporadically observed elevated levels of
cortisol measured in maternal blood peripartum seem not
to be mandatory for normal canine parturition [1,21].
Less attention has been paid so far to uterine endocrine
capabilities in the dog during pregnancy and parturition,
especially those uterine sites not attached to the placenta.
In one study, basal and 12,13-phorbol dibutyrate (PDBu;
protein kinase C stimulator) - mediated capabilities of
canine endometrial and placental explants to produce
PGF2α were determined in vitro, revealing that the
endometrium of pregnant dogs seems to acquire an in-
creased capacity to produce PGF2α immediately prepar-
tum, which - on a tissue weight basis of the explants
used - exceeded even that of the placenta [20]. However,
when taking into account the larger mass of placental
tissue in vivo, the authors inferred that also the placenta
might substantially contribute to the prepartum PGF2α
release. The latter conclusion was confirmed in own
studies [15] which showed an upregulation of COX2 on
the mRNA and protein level in the trophoblast prior to
parturition, rather indicating that the placenta and not the
endometrium is the main source of the prepartum PGF2α
release. Thus, the question regarding the involvement of
prostaglandins synthesized in the interplacental sites in
regulating the processes of pregnancy and parturition in
the bitch is still open. Such a functional interrelationship
has previously been established for other species, e.g., cat-
tle, where increased uterine, intercaruncular expression of
COX2 and PGF2α-receptor (PTGFR, FP) was observed in
animals with induced parturition, indicating the likely
contribution of this increase to labour [22].
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Therefore, with the aim of improving our understanding
of uterine endocrine function during canine gestation,
here, the expression and localization of factors involved in
prostaglandin synthesis and its biological activity, as well
as the expression of progesterone receptor (PGR), were in-
vestigated in the interplacental uterine sites. Based on the
tissue material available, gestational periods from the early
pre-implantation stage until fully established pregnancy
(mid-gestation) were included. Additionally, in order to
investigate the possible functional pathways and aiming to
gain further information on the underlying endocrine
mechanisms, expression of the PG-system was assessed in
mid-pregnant bitches in which PGR function was blocked
with an antigestagen in order to induce preterm luteoly-
sis/abortion.
Methods
Animals and tissue material
As already indicated in a previous study [15], in which
tissue materials from the same animals were used, all
experimental procedures were carried out in accordance
with animal welfare legislation ((permit no. II 25.3-19c20-
15c GI 18/14 and VIG3-19c-20/15c GI 18,14 (Justus-Liebig
University, Giessen) and permit no. Ankara 2006/06
(Faculty of Veterinary Medicine, University of Ankara)).
Clinically healthy, crossbreed bitches, aged 2–8 years
had been assigned to the following groups during selected
time points of pregnancy: pre-implantation (days 8–12,
n = 5), post-implantation (days 18–25, n = 5) and mid-
gestation (days 35–40, n = 5); the time of mating (day 0)
was set as two days after ovulation, which was assessed
by measuring peripheral P4 concentrations (5 > ng/ml)
and by vaginal cytology. Following ovariohysterectomy
tissue samples were collected from the utero-placental
compartment (see in [15]) and the interplacental sites
(full thickness of the uterine wall). The latter, together with
the uterine samples collected from the pre-implantation
stage of pregnancy, were used for the present study.
Tissues were preserved for mRNA-analysis and immu-
nohistochemistry as previously described [15]. The pre-
implantation stage of early pregnancy was confirmed by
uterine flushing of embryos. Based on the temporal devel-
opmental characteristics of canine uterine and placental
tissues, the post-implantation and mid-gestation groups
used in our study relate to periods of canine pregnancy
characterized according to the status of utero-placental
units: either their early formation (post-implantation) or
their full development (mid-gestation, around day 40 of
gestation) [23,24].
Abortion was induced in ten dogs (days 40–45 of preg-
nancy) by application of the antigestagen Aglepristone®
[Alizine® Virbac, 10 mg/Kg bw (2×/24 hrs apart)]; ovario-
hysterectomies were performed 24 hrs (n = 5) and 72 hrs
(n = 5) after the second treatment.
Total RNA extraction, semi-quantitative RT-PCR
TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) was used
for total RNA isolation according to the manufacturer’s
instructions and the RNA content was measured with
a NanoDrop 2000C® spectrophotometer (Thermo Fisher
Scientific AG, Reinach, CH). The elimination of genomic
DNA contamination was achieved by DNase-treatment of
all isolated RNAs with RQ1 RNase-free DNase (Promega,
Dübendorf, CH) following the manufacturer’s protocol.
The reverse transcriptase (RT) reaction was performed
using random hexamers as primers and other reagents
from Applied Biosystems (Foster City, CA, USA) as
previously described [12,18]. For each RT reaction,
100 ng of DNase-treated total RNA were used. The re-
actions were carried out in an Eppendorf Mastercycler®
(Vaudaux-Eppendrf AG, Basel, CH) under the following
experimental conditions: 8 min at 21°C and 15 min at
42°C, then the reaction was stopped by incubation for
5 min at 99°C.
An automated fluorometer ABI PRISM® 7500 Sequence
Detection System (Applied Biosystems) was used for
semi-quantitative Real Time (TaqMan) PCR according to
our previously described protocol [12,18]. All samples
were run in duplicate. Autoclaved water instead of cDNA
and the so-called RT-minus control (samples that were
not reverse transcribed) were used for negative controls.
The following 25 μl reaction mixtures were prepared con-
taining: Fast Start Universal Probe Master Mix (ROX)®
(Roche Diagnostics, Rotkreuz, CH), 200 nM TaqMan
Probe, 300 nM of each primer, 12.5 μl Fast Start Universal
Probe Master Mix (ROX), 5 μl cDNA corresponding to
100 nm total RNA per sample. The cycling conditions
were: denaturation at 95°C for 10 min, 40 cycles at 95°C
for 15 sec, and 60°C for 60 sec. The list of primers and
TaqMan probes labelled with 6-carboxyfluorescein (6-
FAM) and 6-carboxytetramethyl-rhodamine (TAMRA) is
presented in Table 1. All primers were designed using Pri-
mer Express Software (Version 2.0, Applied Biosystems)
and purchased from Microsynth (Balgach, CH). Three
different reference genes were used for normalization:
GAPDH, 18SrRNA and cyclophilin A. The comparative
CT method (ΔΔCT method) was applied for calculating
relative gene expression levels according to a previously
described protocol [12,18] and following the instruc-
tions of the manufacturer of the ABI PRISM® 7500 Se-
quence Detection System. The sample with the lowest
concentration was used as a calibrator for calculating
the relative expression of target genes in this procedure.
The PCR reactions were set up to ensure approximately
100% efficiency of reactions. A commercially available
TaqMan System (primer and probe mixture) of canine-
specific cyclophilin A (TaqMan system) was purchased
from Applied Biosystems (Prod. No. Cf03986523- gH).
Selected PCR products were commercially sequenced
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(Microsynth) in order to confirm the specificity of
amplicons.
Data evaluation
A parametric one-way analysis of variance (ANOVA)
was applied to test for an effect of the observational
group on COX2 (PTGS2), PGT (SLCO2A1) and PGR
mRNA expression levels. In the case of P < 0.05, post-
tests (Tukey-Kramer multiple comparison test) were
performed. Due to the uneven distribution of the data
obtained for uterine mRNA expression of PGFS/AKR1C3,
PGES, FP (PTGFR), EP2 and EP4 (PTGER2 and PTGER4)
and HPGD, the Kruskal-Wallis test (a nonparametric
ANOVA) followed by Dunn’s multiple comparison test
were performed in the event of P < 0.05. In experiments
assessing the expression of target genes after Aglepristone®-
induced preterm luteolysis (abortion), Dunnett’s multiple
comparison test was performed. In the latter case, the
results presented display the n-fold change in target
gene mRNA-levels compared to their expression in
mid-gestation, which was used as the non-treated control.
GraphPad 3.06 (GraphPad Software, Inc., San Diego,
California, USA) was used for all tests. Data are presented
as the mean ± standard deviation.
Table 1 List of primers and taqman probes used for semi-quantitative RT-PCR
Primer Accession numbers Primer sequence Product lenght (bp)
GAPDH (forward) AB028142 5′-GCT GCCAAATAT GACGACATC A-3′ 75bp
GAPDH (reverse) 5′-GTA GCC CAG GAT GCC TTT GAG-3′
GAPDH (TaqMan Probe) 5′-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3′
18SrRNA (forward) FJ797658 5′-GTC GCT CGC TCC TCT CCT ACT-3′ 125bp
18SrRNA (reverse) 5′-GGC TGA CCG GGT TGG TTT-3′
18SrRNA (TaqMan Probe) 5′-ACA TGC CGA CGG GCG CTG AC-3′
PGR (forward) NM_001003074 5′-CGA GTC ATT ACC TCA GAA GAT TTG TTT-3′ 113bp
PGR (reverse) 5′-CTT CCA TTG CCC TTT TAA AGA AGA-3′
PGR (TaqMan Probe) 5′-AAG CAT CAG GCT GTC ATT ATG GTG TCC TAA CTT-3′
COX2 (forward) HQ110882 5′-GGA GCA TAA CAG AGT GTG TGA TGT G-3′ 87bp
COX2 (reverse) 5′-AAG TAT TAG CCT GCT CGT CTG GAA T-3′
COX2 (TaqMan Probe) 5′-CGC TCA TCA TCC CAT TCT GGG TGC-3′
PGFS/AKR1C3 (forward) NM_001012344 5′-AGG GCT TGC CAA GTC TAT TGG-3′ 74bp
PGFS/AKR1C3 (reverse) 5′-GCC TTG GCT TGC TCA GGA T-3′
PGFS/AKR1C3 (TaqMan Probe) 5′-TCC AAC TTT AAC CGC AGG CAG CTG G-3′
PGES (forward) NM_001122854 5′-GTC CTG GCG CTG GTG AGT-3′ 89bp
PGES (reverse) 5′-ATG ACA GCC ACC ACG TAC ATC T-3′
PGES (TaqMan Probe) 5′-TCC CAG CCT TCC TGC TCT GCA GC-3′
PTGFR (FP) (forward) NM_001048097 5′-ACC AGT CGA ACA TCC TTT GCA-3′ 86bp
PTGFR (FP) (reverse) 5′-GGC CAT CAC ACT GCC TAG AAA-3′
PTGFR (FP) (TaqMan Probe) 5′-CAT GGT GTT CTC CGG TCT GTG CCC-3′
PTGER2 (forward) AF075602 5′- CAC CCT GCT GCT GCT TCT C-3′ 78bp
PTGER2 (reverse) 5′-CGG TGC ATG CGG ATG AG-3′
PTGER2 (TaqMan Probe) 5′-TGC TCG CCT GCA ACT TTC AGC GTC-3′
PTGER4 (forward) NM_001003054 5′-AAA TCA GCA AAA ACC CAG ACT TG-3′ 96bp
PTGER4 (reverse) 5′-GCA CGG TCT TCC GCA GAA -3′
PTGER4 (TaqMan Probe) 5′-ATCCGA ATT GCT GCT GTG AAC CCT ATC C-3′
PGT (forward) NM_001011558 5′-TGC AGC ACT AGG AAT GCT GTT C-3′ 116bp
PGT (reverse) 5′-GGG CGC AGA GAA TCA TGG A-3′
PGT (TaqMan probe) 5′-TCT GCA AAC CAT TCC CCG CGT G-3′
HPGD (forward) NM_001284477 5′-GGC AGC GAA TCT CAT GAA CAG-3′ 93bp
HPGD (reverse) 5′-TCT TCT TTC TCA ATG GAT TCA AGGA-3′
HPGD (TaqMan Probe) 5′-TGA ATG CCA TTT GCC CAG GCT TTG-3′
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Immunohistochemistry
Our standard immunohistochemistry (IHC) procedure
was applied on formalin-fixed, paraffin-embedded sections
following the protocol described previously [12,17,25].
The list of primary antibodies and isotype controls is pre-
sented in Table 2. Briefly: after deparaffinization in xylol,
slides were rehydrated in a graded ethanol series and
washed under running tap water for 5 min. Antigen
retrieval was performed in 10 mM citrate buffer pH 6.0 at
room temperature for 5 min followed by microwave
irradiation in an oven run at 560 W for 15 min and for
20 min at room temperature. Endogenous peroxidase
activity was quenched by incubating the sections in 0.3%
hydrogen peroxide in methanol for 30 min. The nonspe-
cific binding sites were blocked with either 10% horse
serum or 10% normal goat serum, depending on the sec-
ondary antibody used in experiments. Thereafter, slides
were overlaid with primary antibodies and incubated over-
night at 4°C. Two negative controls were performed: (a)
omitting the primary antibody, and (b) antiserum-specific
isotype controls at the same dilution and protein concen-
tration as the primary antibody. The incubation with
secondary antibodies was for 30 min at room temperature
using 1:100 dilution. Following biotinylated secondary
antibodies were used: horse anti mouse IgG BA-2000,
goat anti-guinea pig IgG BA-7000, goat anti rabbit IgG
BA-1000 and horse anti goat IgG BA-9500, all from
Vector Laboratories Inc., Burlingame, CA 94010, USA.
Signals were enhanced with the streptavidin-avidin-
peroxidase Vectastain ABC kit (Vector Laboratories),
for 30 min at room temperature. Peroxidase activity
was detected with the DAB substrate Kit according to
the manufacturer's instructions (Dako North America, Inc.,
City, Country). Post-staining was done using hematoxylin,
slides were mounted in Histokit (Assistant Osterode,
Germany).
Results
Semi-quantitation of uterine gene expression from
pre-implantation until mid-gestation
Expression profiles of COX2 (PTGS2), PGFS/AKR1C3,
FP (PTGFR), PGES, the PGE2 receptors EP2 and EP4
(PTGER2 and PTGER4), HPGD, the prostaglandin trans-
porter (PGT, SLCO2A1) and the progesterone receptor
(PGR) were assessed in uterine interplacental sites using
semi-quantitative Real Time (TaqMan) RT-PCR.
Whereas the expression of COX2 was low and did
not change from pre-implantation until mid-gestation
Table 2 List of primary antibodies and isotype controls used for immunohistochemistry
Name/antigen Clone Company Immunogen Concentration Species/type
COX2 clone 33 BD Pharmingen
Heidelberg Germany
anti-rat COX-2 IgG 1:100 mouse
monoclonal
PGT (G-17) Sc-103085 Santa Cruz Biotechnology
CA, USA
IgG against human PGT 1:100 goat
polyclonal
PGFS/AKR1C3 custom made canine-specific
antibody (Gram et al., 2013 [17])
Eurogentec Seraing
Belgium
IgG against canine-specific peptide
sequence DTLFATHPDYPFNDED,
C-terminal amino acids 309–324
1:750 guinea pig
polyclonal
PGES custom made canine-specific
antibody (Kautz et al., 2014 [26])
Eurogentec Seraing
Belgium
IgG against canine-specific peptide
sequence RSDQDVDRCLRAHRND,
C-terminal amino acids 61–76
1:300 guinea pig
polyclonal
HPGD custom made canine-specific
antibody (Gram et al., 2013 [17])
Eurogentec Seraing
Belgium
IgG against canine-specific peptide
sequence HFQDYETTPFHAKTQ,
C-terminal amino acids 252–266
1:750 guinea pig
polyclonal
EP2 catalog no. 101770 Cayman Chemicals
MI, USA
IgG against human EP2, C-terminal
amino acids 335–358
1:200 rabbit
polyclonal
EP4 catalog no. 101775 Cayman Chemicals
MI, USA
IgG against human EP4, C-terminal
amino acids 459–488
1:100 rabbit
polyclonal
Isotype control IgG Vector Laboratories Inc.,
Burlingame, CA, USA
− Same protein
concentration as
primary antibody
mouse
Isotype control IgG Vector Laboratories Inc.,
Burlingame, CA, USA
− Same protein
concentration as
primary antibody
rabbit
Isotype control IgG Vector Laboratories Inc.,
Burlingame, CA, USA
− Same protein
concentration as
primary antibody
goat
Isotype control IgG Vector Laboratories Inc.,
Burlingame, CA, USA
− Same protein
concentration as
primary antibody
guinea pig
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(P = 0.92) (Figure 1A), the uterine expression of PGFS/
AKR1C3 was strongly modulated over time (P = 0.0005),
increasing significantly from the pre-implantation to the
post-implantation stage (P < 0.01) (Figure 1C), with the
apparent decrease towards mid-gestation being not signifi-
cant (P > 0.05). A significant effect of time (P < 0.0001)
was observed for the FP receptor with values continuously
decreasing from pre-implantation until mid-gestation
(P < 0.01) (Figure 2A). There was a significant effect of
time for PGES mRNA expression (P = 0.03) (Figure 1E),
which increased gradually throughout the observational
period, reaching the highest mRNA levels at mid-gestation
(P < 0.01). Of the two PGE2 receptors, only the expres-
sion of EP2 (PTGER2) changed significantly over time
(P = 0.003), being significantly diminished at mid-gestation
compared with pre-implantation (Figure 2C). In contrast,
Figure 1 Expression of cyclooxygenase 2 (COX2, PTGS2), prostaglandin F2α synthase (PGFS) and of prostaglandin E2 synthase (PGES).
Expression of COX2 (PTGS2), PGFS/AKR1C3 and PGES was determined by Real Time (TaqMan) PCR (mean ± SD) in the interplacental sites of
canine uterus from the pre-implantation period until mid-gestation (A,C,E) and during Aglepristone®-induced luteolysis/abortion (B,D,F,
compared with the mid-gestation group as a non-treated control). Bars with different asterisks differ either at P < 0.01 in (C) and (E), or at
P < 0.05 in (B) and (F).
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the expression of EP4 varied widely among samples and
remained statistically unaffected (P = 0.29) (Figure 2E).
The expression of PGT (SLCO2A1) was significantly
altered throughout the observational period (P = 0.01),
increasing simultaneously with PGES mRNA and being
higher in mid-pregnant dogs compared with the pre-
implantation stage (P < 0.05) (Figure 3A). Although an ap-
parent decrease was observed for HPGD mRNA expression
with the progression of pregnancy, however, mostly because
of very high variations in the specific mRNA content, the
changes observed were statistically not significant (P = 0.13)
(Figure 3C). As for PGR mRNA levels, after initially
high expression during pre-implantation, they decreased
afterwards, reaching significantly lower expression levels
post-implantation and during mid-gestation (P < 0.05)
(Figure 3E).
Figure 2 Expression of PGF2α receptor (FP, PTGFR) and of PGE2 receptors, EP2 (PTGER2) and EP4 (PTGER4). Expression of FP (PTGFR) and
of EP2 and EP4 (PTGER2 and PTGER4, respectively) was determined by Real Time (TaqMan) PCR (mean ± SD) in the interplacental sites of canine
uterus from the pre-implantation period until mid-gestation (A,C,E) and during Aglepristone®-induced luteolysis/abortion (B,D,F, compared with
the mid-gestation group as non-treated control). Bars with different asterisks differ either at P < 0.01 in (A) or at P < 0.05 in (C,D).
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The effects of antiprogestin treatment on uterine gene
expression
Uterine gene expression was assessed by semi-quantitative
Real Time PCR in uteri obtained from antigestagen-
treated dogs. For all parameters, samples derived from
the mid-gestation group served as non-treated controls in
the statistical evaluation applying Dunnett’s multiple com-
parison test. A significant increase in COX2 (PTGS2), PGES
and PGT (SLCO2A1) expression was observed 24 hrs
after the second treatment with Aglepristone® (P < 0.05)
(Figure 1B, Figure 1F and Figure 3B). The increase in EP2
(PTGER2) levels was more pronounced (P < 0.05) after 72 h
(Figure 2D). An apparent suppression of PGR expression
was already observed 24 h after the antigestagen treatment
and it was significantly downregulated (P < 0.001) at 72 h
(Figure 3F). The expression of PGFS/AKR1C3, FP (PTGFR),
Figure 3 Expression of prostaglandin transporter (PGT, SLCO2A1), 15-prostaglandin dehydrogenase (HPGD) and progesterone receptor
(PGR). Expression of PGT (SLCO2A1), HPGD and PGR was determined by Real Time (TaqMan) PCR (mean ± SD) in the interplacental sites of canine
uterus from the pre-implantation period until mid-gestation (A,C,E) and during Aglepristone®-induced luteolysis/abortion (B,D,F, compared with
the mid-gestation group as non-treated control). Bars with different asterisks differ either at P < 0.001 in (F) or at P < 0.05 (A,B,E).
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Figure 4 (See legend on next page.)
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EP4 (PTGER4) and HPGD was unaffected (P > 0.05)
(Figure 1D, Figure 2B, Figure 2F, Figure 3D).
Immunohistochemical (IHC) localization of gene expression
All antibodies applied in this study were used in our
previous projects and found to be specific for the canine
species [15,17,26]. No or only very weak IHC signals
were observed in the uterine endometrium for COX2
(PTGS2), whereas myometrium stained strongly in all
samples investigated (Figure 4A). A similar signal distri-
bution pattern was observed following the antigestagen
treatment (Figure 4D,E). Additionally, utero-placental
cross-sections (full thickness, middle part of the placen-
tal girdle avoiding marginal hematoma) obtained from
the same animals in which abortion was induced with
an antigestagen were included in the experiment and
stained, revealing the COX2 (PTGS2) protein expres-
sion pattern previously described [15], i.e., strong COX2
signals were spread over the entire trophoblast during
induced parturition coinciding with a substantial pre-
partum increase of PGF2α, while only weak signals were
visible in the adjacent endometrial tissues (Figure 4B,C).
After low and only barely detectable expression of PGFS/
AKR1C3 protein during the pre-implantation stage of preg-
nancy, its uterine expression was clearly detectable, display-
ing a tendency towards over-staining, post-implantation
and was localized predominantly to the superficial luminal
endometrial epithelium (Figure 4F,G), while only weak
staining was observed in the uterine glands and in myo-
metrium (not shown); distribution pattern and staining
intensity did not change in Aglepristone®-treated dogs
(Figure 4J,K). As for COX2 (PTGS2), the expression
pattern of PGFS/AKR1C3 protein in the interplacental
sites was comparable with its previously published [17]
distribution in the utero-placental compartment, revealing
the co-localization of PGFS/AKR1C3 with COX2 expres-
sion (Figure 4H,I).
The expression of PGES (Figure 5A-C) showed a
similar distribution pattern from the pre-implantation
until mid-gestation and at induced parturition-derived
uterine samples, with signals localized in endometrial
epithelial cells, weaker staining in the uterine stroma,
and myometrial signals, which became clearly detectable
at induced parturition (Figure 5C). A similar staining
pattern was observed for the two PGE2-receptors, EP2
and EP4, with signals evenly distributed between the endo-
metrial and myometrial compartments (Figure 5D-G). The
expression of PGT (SLCO2A1) was co-localized with other
PG-system members, however, with myometrial signals,
appearing stronger following the antigestagen treatment
(Figure 5H,I). A similar localization pattern, but with
widely varying IHC signals among individual animals, was
noted for HPGD (Figure 5J). As for EP2 and EP4, the signal
distribution and intensity did not change during induced
preterm parturition/abortion (Figure 5K,L).
Discussion
By showing strong functional interrelationships, and to
some extent opposite effects, prostaglandins (PGs) un-
equivocally play an important role in regulating repro-
ductive functions. Thus, whereas PGE2 was shown to be
involved, e.g., in softening the cervix during parturition
[27,28], PGF2α is the best-known luteolytic factor, while
both PGs are involved in coordinating myometrial con-
tractile activity [29-31]. Accordingly, uterine expression
of the respective genes encoding for factors involved in
PGs synthesis and metabolism, the so-called prostaglandin
system, was shown in several species, such as cattle [22],
sheep [32,33] and rats [34].
In the present study, the expression and localization of
the PG-system was investigated in canine interplacental
uterine tissues at selected time points of pregnancy, i.e.,
pre-implantation, post-implantation and mid-gestation
(there was no tissue material available for experiments
(See figure on previous page.)
Figure 4 Immunohistochemical localization of cyclooxygenase 2 (COX2, PTGS2) and prostaglandin F2α synthase (PGFS/AKR1C3).
Immunohistochemical (IHC) localization of COX2 (PTGS2) at interplacental uterine sites during mid-gestation (A), as well as in the utero-placental
compartment (B,C), and interplacental uterine sites (D,E) during Aglepristone® (Agl.)-induced abortion. IHC localization of PGFS/AKR1C3 in the
uterus pre-implantation (F), post-implantation (G) and in the utero-placental compartment (H,I) and interplacental uterine sites (J,K) during
Aglepristone® (Agl.)-induced abortion. Whereas no or only very weak COX2 IHC signals are observed in uterine endometrium (open arrows = surface
luminal epithelium, solid arrowhead = uterine gland), clearly visible staining is localized in myometrium (A). In the utero-placental compartment during
Agl.-induced parturition, placental COX2 is localized to the fetal trophoblast cells (solid arrows in B); there are only very weak signals in the uterine
glands (solid arrowhead in C), but strong ones are present in myometrium (open arrowhead in C). In the interplacental sites, following Agl. treatment,
strong COX2 staining is localized in myometrium (open arrowhead in E), and only very weak staining is present in surface (luminal) uterine epithelium
(open arrows in D) and uterine glands (solid arrowheads in D and E). No or only very weak uterine signals are observed for PGFS/AKR1C3 pre-
implantation (F). Following implantation, PGFS/AKR1C3 protein is localized in surface (luminal) uterine epithelium and endometrial superficial
glands (open and solid arrows in G). In the utero-placental compartment during Agl.-induced parturition, placental PGFS/AKR1C3 protein is lo-
calized to the fetal trophoblast cells (solid arrows in H); strong signals are localized also in the superficial endometrial glands, the so-called glan-
dular chambers (open arrows in I). Within the interplacental uterine sites, in Agl.-treated animals, PGFS/AKR1C3 staining is localized predominantly in
surface (luminal) uterine epithelium (open arrows in J); the open and solid arrowheads in (K) indicate myometrium and uterine glands, respectively, with
barely detectable signals.
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Figure 5 (See legend on next page.)
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from the interplacental sites from dogs during normal
perpartum luteolysis).
Our data clearly indicate the basic capability of these
tissues to synthesize and respond to prostaglandins,
because the expression of all major components of the
PG-system was detectable in all tissue samples investi-
gated, both at the mRNA and protein level.
In general, the gene expression patterns observed
resembled their expression in the corresponding utero-
placental compartments [15,17]. The expression of COX2
remained low until mid gestation, and the post-implantation
period was characterized by increased PGFS/AKR1C3
expression. This, together with the gradually rising PGES
expression levels and the concomitant presence of the
respective prostaglandin receptors, imply a local role
of these hormones during canine decidualization and
implantation, as indicated previously [15,17]. Also, in
agreement with our previous conclusion [17], a locally
increased HPGD expression during earlier stages of
pregnancy, which - in the present study - shows up as
a tendency, could additionally restrict and coordinate
the endocrine/paracrine effects of PGs.
The antigestagen-mediated blocking of the uterine
PGR receptor, whose expression was significantly down-
regulated after implantation, resulted in upregulated
uterine COX2 and PGES expression, thereby resembling
their expression patterns in utero-placental compartments
during normal and preterm parturition/abortion [15].
Interestingly, however, their localization patterns did not
change significantly in response to the antigestagen treat-
ment and, especially for COX2, the strongest signals were
still observed in the myometrium. This was compared
with their distribution pattern in the corresponding utero-
placental compartments, confirming their presence in the
fetal part of the placenta, i.e., in the trophoblast cells, as
described in our previous research [15,17]. Less dramatic
changes, but also with an overall expression pattern re-
sembling that observed in utero-placental samples, pertain
to the uterine expression of PGFS/AKR1C3, FP, EP4 and
HPGD in antigestagen-treated bitches.
Consequently, based on our observations, we infer that
the upregulated uterine expression of COX2 and PGES
may originate mostly in the myometrial compartment,
because their localization pattern did not differ signifi-
cantly following treatment with Aglepristone®. This is in
contrast to observations made in cattle where the strongly
upregulated COX2 expression was predominantly local-
ized in surface epithelial cells, both in animals undergoing
spontaneous labour and those in which it was induced
prematurely [22,35]. However, as in cattle, in dogs PGs
derived from the interplacental uterine sites seem to
contribute primarily to myometrial contractility in con-
junction with fetal expulsion, with the utero-placental
compartment, however, remaining an important source of
PGs around term [36,37].
The alterations in placental feto-maternal communica-
tion occurring in response to the local withdrawal of
progesterone appear to be important for subsequently
increasing output of the luteolytic hormone PGF2α,
which with respect to the placenta must originate in the
fetal component, i.e., in the trophoblast cells, where PGs
synthesizing enzymes are expressed and localized. This
conclusion seems to relate to both the bovine and canine
species [15,36,37].
Furthermore, also in accordance with our previous
studies [15], the upregulated expression of COX2 during
induced parturition points towards the substantial role
of COX2 (PTGS2) as a rate-limiting factor in provision
of prepartum prostaglandins in the dog. Such a role of
COX2 as a rate-limiting factor has also been observed in
the horse [38], where blocking of endometrial COX2
expression by the conceptus at day 15 of early pregnancy
prevented PGF2α-induced luteal regression and resulted
in continuation of pregnancy.
At the functional level, our descriptive findings con-
cerning the basal capability of canine uterine and placental
tissues to produce and respond to PGs, are not conclusive
and will require further studies including, e.g., measure-
ments of the local PGs content within those tissues during
different stages of canine gestation.
Conclusions
Our study presents the expression and localization
patterns of factors involved in the synthesis of prosta-
glandins, the so-called prostaglandin-system, in canine
interplacental uterine sites at selected times of pregnancy
(pre-implantation, post-implantation and mid-gestation).
Additionally, changes in the expression and availability of
these factors and, hence, their potential contribution to
the process of parturition, have been investigated in dogs
(See figure on previous page.)
Figure 5 Immunohistochemical localization of prostaglandin E2 synthase (PGES), PGE2 receptors EP2 and EP4 (PTGER2 and PTGER4),
prostaglandin transporter (PGT, SLCO2A1) and of 15-prostaglandin dehydrogenase (HPGD). Immunohistochemical (IHC) localization of:
(A-C) PGES, and (D-F) EP2 (PTGER2) in interplacental uterine sites during mid-gestation and during Aglepristone® (Agl.)-induced abortion. (G)
Representative picture of EP4 (PTGER4) expression in interplacental site during Aglepristone® (Agl.)-induced abortion in mid-gestation dog. (H,I)
Expression of PGT (SLCO2A1) in interplacental uterine site during mid-gestation and during Aglepristone® (Agl.)-induced abortion. (J-L) Uterine
expression of HPGD in interplacental uterine sites during mid-gestation and after Aglepristone® (Agl.) treatment. Open arrows = surface (luminal)
uterine epithelium, solid arrowheads = uterine glands, open arrowheads in (C), (F), (K), (L) =myometrium.
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in which progesterone receptor function was blocked by
an antigestagen.
Based on the observations presented herein, in addition
to prostaglandins of placental origin, the canine pregnant
uterus also appears to be an organ actively involved in
prostaglandin synthesis during canine parturition, most
probably contributing predominantly to myometrial con-
tractility. From a practical point of view, our findings can
help us to better understand the mechanisms responsible
for parturition in the dog, especially because decreased
synthesis of prostaglandins and/or reduced uterine sensi-
tivity to them could result in serious clinical conditions
such as uterine inertia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MPK: Idea of the study, collecting tissue samples, Real Time PCR experiments,
statistical evaluation, interpretation of data, manuscript writing. EK: RNA
isolation, Real Time PCR experiments, immunohistochemical procedures. EH:
Tissue preparation and processing, immunohistochemical procedures. BH:
coordination of animal experiments and collection of tissue samples,
knowledge transfer, critical discussion of the data, editing of the manuscript.
AB: knowledge transfer, critical discussion of the data, editing of the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
Supported by the Swiss National Science Foundation (SNSF) research grant
number 408 31003A_140947. Authors are grateful to Dr. Barry Bavister for
careful editing of the manuscript. The support of Virbac, France, in providing
Aglepristone® is highly appreciated.
Author details
1Institute of Veterinary Anatomy, Vetsuisse Faculty, University of Zurich,
Zurich, Switzerland. 2Clinic for Obstetrics, Gynecology and Andrology of
Large and Small Animals, Justus-Liebig University Giessen, Giessen, Germany.
Received: 25 February 2014 Accepted: 8 May 2014
Published: 30 May 2014
References
1. Hoffmann B, Hoveler R, Nohr B, Hasan SH: Investigations on hormonal
changes around parturition in the dog and the occurrence of
pregnancy-specific non conjugated oestrogens. Exp Clin Endocrinol
Diabetes 1994, 102:185–189.
2. Nishiyama T, Tsumagari S, Ito M, Kimura J, Watanabe G, Taya K, Takeishi M:
Immunohistochemical study of steroidogenic enzymes in the ovary and
placenta during pregnancy in the dog. Anat Histol Embryol 1999,
28:125–129.
3. Hoffmann B, Buesges F, Engel E, Kowalewski MP, Papa PC: Regulation of
corpus luteum-function in the bitch. Reprod Domest Anim 2004,
39:232–240.
4. Kowalewski MP: Luteal regression vs. prepartum luteolysis: Regulatory
mechanisms governing canine corpus luteum function. Reprod Biol 2014,
14(2):89–102. doi: 10.1016/j.repbio.2013.11.004.
5. Kowalewski MP: Endocrine and molecular control of luteal and placental
function in dogs: a review. Reprod Domest Anim 2012, 47(Suppl 6):19–24.
6. Concannon PW, McCann JP, Temple M: Biology and endocrinology of
ovulation, pregnancy and parturition in the dog. J Reprod Fertil Suppl
1989, 39:3–25.
7. Concannon PW, Powers ME, Holder W, Hansel W: Pregnancy and
parturition in the bitch. Biol Reprod 1977, 16:517–526.
8. Hoffmann B, Hoveler R, Hasan SH, Failing K: Ovarian and pituitary function
in dogs after hysterectomy. J Reprod Fertil 1992, 96:837–845.
9. Olson PN, Bowen RA, Behrendt MD, Olson JD, Nett TM: Concentrations of
progesterone and luteinizing hormone in the serum of diestrous bitches
before and after hysterectomy. Am J Vet Res 1984, 45:149–153.
10. Kowalewski MP, Beceriklisoy HB, Aslan S, Agaoglu AR, Hoffmann B: Time
related changes in luteal prostaglandin synthesis and steroidogenic
capacity during pregnancy, normal and antiprogestin induced luteolysis
in the bitch. Anim Reprod Sci 2009, 116:129–138.
11. Kowalewski MP, Fox B, Boos A, Reichler I: Prostaglandin E2 (PGE2) - the
luteotropic factor of the gonadotropin-independent phase in the dog
acts at the level of steroidogenic acute regulatory (STAR) protein.
Reprod Dom Anim 2012, 47(Suppl. 2):32.
12. Kowalewski MP, Schuler G, Taubert A, Engel E, Hoffmann B: Expression of
cyclooxygenase 1 and 2 in the canine corpus luteum during diestrus.
Theriogenology 2006, 66:1423–1430.
13. Kowalewski MP, Fox B, Gram A, Boos A, Reichler I: Prostaglandin E2 functions
as a luteotrophic factor in the dog. Reproduction 2013, 145:213–226.
14. Baan M, Taverne MA, de Gier J, Kooistra HS, Kindahl H, Dieleman SJ, Okkens
AC: Hormonal changes in spontaneous and aglepristone-induced parturition
in dogs. Theriogenology 2008, 69:399–407.
15. Kowalewski MP, Beceriklisoy HB, Pfarrer C, Aslan S, Kindahl H, Kucukaslan I,
Hoffmann B: Canine placenta: a source of prepartal prostaglandins during
normal and antiprogestin-induced parturition. Reproduction 2010, 139:655–664.
16. Nohr B, Hoffmann B, Steinetz BE: Investigation of the endocrine control of
parturition in the dog by application of an antigestagen. J Reprod Fertil Suppl
1993, 47:542–543.
17. Gram A, Buchler U, Boos A, Hoffmann B, Kowalewski MP: Biosynthesis and
Degradation of Canine Placental Prostaglandins: Prepartum Changes in
Expression and Function of Prostaglandin F2alpha-Synthase (PGFS,
AKR1C3) and 15-Hydroxyprostaglandin Dehydrogenase (HPGD).
Biol Reprod 2013, 89:2.
18. Kowalewski MP, Meyer A, Hoffmann B, Aslan S, Boos A: Expression and
functional implications of Peroxisome Proliferator-Activated Receptor
Gamma (PPARgamma) in canine reproductive tissues during normal
pregnancy and parturition and at antiprogestin induced abortion.
Theriogenology 2011, 75:877–886.
19. Kowalewski MP, Michel E, Gram A, Boos A, Guscetti F, Hoffmann B, Aslan S,
Reichler I: Luteal and placental function in the bitch: spatio-temporal
changes in prolactin receptor (PRLr) expression at dioestrus, pregnancy
and normal and induced parturition. Reprod Biol Endocrinol 2011, 9:109.
20. Luz MR, Bertan CM, Binelli M, Lopes MD: In vitro PGF2α production by
endometrium and corpus luteum explants from pregnant and
nonpregnant diestrus bitches and placental explants from pregnant
bitches. Theriogenology 2006, 66:1442–1447.
21. Concannon PW, Butler WR, Hansel W, Knight PJ, Hamilton JM: Parturition
and lactation in the bitch: serum progesterone, cortisol and prolactin.
Biol Reprod 1978, 19:1113–1118.
22. Wehbrink D, Hassig M, Ritter N, Zerbe H, Bleul U, Boos A: Immunohistochemical
demonstration of cyclooxygenase-2 (COX-2) and prostaglandin receptors EP2
and FP expression in the bovine intercaruncular uterine wall around term.
Anim Reprod Sci 2008, 106:241–254.
23. Amoroso EC: Placentation. In Marshall's physiology of reproduction. Edited
by Parkes AS. London: Longmans Green; 1952:127–316.
24. Kehrer A: Zur entwicklung und ausbildung des chorions der placenta
zonaria bei katze, hund und fuchs. Zeitschrift fur Anatomie und
Entwicklungsgeschichte 1973, 143:25–42.
25. Kowalewski MP, Mason JI, Howie AF, Morley SD, Schuler G, Hoffmann B:
Characterization of the canine 3beta-hydroxysteroid dehydrogenase and
its expression in the corpus luteum during diestrus. J Steroid Biochem Mol Biol
2006, 101:254–262.
26. Kautz E, Gram A, Aslan S, Ay SS, Selçuk M, Kanca H, Koldaş E, Akal E, Karakaş
K, Findik M, Boos A, Kowalewski MP: Expression of genes involved in the
embryo-maternal interaction in the early pregnant canine uterus.
Reproduction 2014, 147(5):703–717.
27. Stys SJ, Dresser BL, Otte TE, Clark KE: Effect of prostaglandin E2 on cervical
compliance in pregnant ewes. Am J Obstet Gynecol 1981, 140:415–419.
28. Fuchs AR, Goeschen K, Rasmussen AB, Rehnstrom JV: Cervical ripening and
plasma prostaglandin levels. Comparison of endocervical and extra-amniotic
PGE2. Prostaglandins 1984, 28:217–227.
29. Senior J, Marshall K, Sangha R, Clayton JK: In vitro characterization of
prostanoid receptors on human myometrium at term pregnancy.
Br J Pharmacol 1993, 108:501–506.
Kowalewski et al. Reproductive Biology and Endocrinology 2014, 12:46 Page 13 of 14
http://www.rbej.com/content/12/1/46
30. Senior J, Sangha R, Baxter GS, Marshall K, Clayton JK: In vitro
characterization of prostanoid FP-, DP-, IP- and TP-receptors on the
non-pregnant human myometrium. Br J Pharmacol 1992, 107:215–221.
31. Senior J, Marshall K, Sangha R, Baxter GS, Clayton JK: In vitro
characterization of prostanoid EP-receptors in the non-pregnant human
myometrium. Br J Pharmacol 1991, 102:747–753.
32. Wu WX, Ma XH, Yoshizato T, Shinozuka N, Nathanielsz PW: Increase in
prostaglandin H synthase 2, but not prostaglandin F2alpha synthase
mRNA in intrauterine tissues during betamethasone-induced premature
labor and spontaneous term labor in sheep. J Soc Gynecol Investig 2001,
8:69–76.
33. Gyomorey S, Gupta S, Lye SJ, Gibb W, Labrie F, Challis JR: Temporal
expression of prostaglandin H synthase type 2 (PGHS-2) and P450(C17)
in ovine placentomes with the natural onset of labour. Placenta 2000,
21:478–486.
34. Satoh H, Watanabe K, Kawaminami M, Kurusu S: A comprehensive
immunohistochemistry of prostaglandins F2alpha and E2 synthetic
enzymes in rat ovary and uterus around parturition. Prostaglandins Other
Lipid Mediat 2013, 106:23–28.
35. Fuchs AR, Rust W, Fields MJ: Accumulation of cyclooxygenase-2 gene
transcripts in uterine tissues of pregnant and parturient cows: stimulation
by oxytocin. Biol Reprod 1999, 60:341–348.
36. Arosh JA, Banu SK, Chapdelaine P, Fortier MA: Temporal and tissue-specific
expression of prostaglandin receptors EP2, EP3, EP4, FP, and cyclooxygenases
1 and 2 in uterus and fetal membranes during bovine pregnancy.
Endocrinology 2004, 145:407–417.
37. Schuler G, Teichmann U, Kowalewski MP, Hoffmann B, Madore E, Fortier MA,
Klisch K: Expression of cyclooxygenase-II (COX-II) and 20alpha-hydroxysteroid
dehydrogenase (20alpha-HSD)/prostaglandin F-synthase (PGFS) in bovine
placentomes: implications for the initiation of parturition in cattle. Placenta
2006, 27:1022–1029.
38. Boerboom D, Brown KA, Vaillancourt D, Poitras P, Goff AK, Watanabe K, Dore
M, Sirois J: Expression of key prostaglandin synthases in equine
endometrium during late diestrus and early pregnancy. Biol Reprod 2004,
70:391–399.
doi:10.1186/1477-7827-12-46
Cite this article as: Kowalewski et al.: Interplacental uterine expression of
genes involved in prostaglandin synthesis during canine pregnancy and
at induced prepartum luteolysis/abortion. Reproductive Biology and
Endocrinology 2014 12:46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kowalewski et al. Reproductive Biology and Endocrinology 2014, 12:46 Page 14 of 14
http://www.rbej.com/content/12/1/46
